Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet.

PloS one - 1 Jan 2012

Solverson Patrick, Murali Sangita G, Litscher Suzanne J, Blank Robert D, Ney Denise M

Abstract excerpt

PURPOSE: Phenylketonuria (PKU), caused by phenylalanine (phe) hydroxylase loss of function mutations, requires a low-phe diet plus amino acid (AA) formula to prevent cognitive impairment. Glycomacropeptide (GMP), a low-phe whey protein, provides a palatable alternative to AA formula. Skeletal fra...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Absorptiometry, Photon
Share to Biomechanical Phenomena
Share to Caseins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diet, Protein-Restricted

Share to Elastic Modulus

Share to Phenylalanine Hydroxylase

Share to Phenylketonurias

Source

Open in PubMed Open full text

Identifiers

PMID: 23028819
DOI: 10.1371/journal.pone.0045165
PMCID: PMC3445501

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23028819-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet.PMID 23028819Read ↗

Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria.Semantic proximity Read ↗

Advances in the nutritional and pharmacological management of phenylketonuria.Semantic proximity Read ↗

Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice.Semantic proximity Read ↗

Differential Effects of Dietary Fat Content and Protein Source on Bone Phenotype and Fatty Acid Oxidation in Female C57Bl/6 Mice.Semantic proximity Read ↗

The mechanical phenotype of biglycan-deficient mice is bone- and gender-specific.Semantic proximity Read ↗

Risk factors for developing mineral bone disease in phenylketonuric patients.Semantic proximity Read ↗

4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta.Semantic proximity Read ↗

Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.Semantic proximity Read ↗

Adenine-induced chronic kidney disease induces a similar skeletal phenotype in male and female C57BL/6 mice with more severe deficits in cortical bone properties of male mice.Semantic proximity Read ↗

Phenotypic characterization of mice bred for high and low peak bone mass.Semantic proximity Read ↗

Behavioral Phenotyping of the Pahenu2 Mouse Model for Phenylketonuria-A Scoping Review and Future Perspectives.Semantic proximity Read ↗

Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.